DMKJ
CGEM icon

David M. Knott Jr’s Cullinan Oncology CGEM Stock Holding History

David M. Knott Jr’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
69,182
+44,982
+186% +$668K 0.67% 30
2026
Q1 		$344K Buy
+24,200
New +$311K 0.2% 51

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

David M. Knott Jr's CGEM Position: Q2 2026 in Review

David M. Knott Jr increased its Cullinan Oncology (CGEM) stake by 186% in Q2 2026, buying an estimated $668K and bringing the position to 69,182 shares worth $1.26M. The position accounts for 0.67% of the portfolio, ranked #30.

David M. Knott Jr first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • David M. Knott Jr held 69,182 shares of Cullinan Oncology worth $1.26M as of Q2 2026.
  • David M. Knott Jr bought 44,982 Cullinan Oncology shares in Q2 2026, an estimated $668K.
  • Cullinan Oncology made up 0.67% of David M. Knott Jr's portfolio in Q2 2026, its #30 holding.
  • David M. Knott Jr first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.